Differential expression of uPA in chronic hepatitis B and C, liver cirrhosis and hepatocellular carcinoma: Comparison with normal liver tissues and liver metastatic tumors

International Journal of Cancer Research

Volumn 3, Issue 1, 2007, Pages 25-32

  Bidgoli, Sepideh Arbabi ^a,b   Zaverhei, Mansour Djamali ^b   Mohagheghi, Mohamadali ^c   Yazdanmehr, Bahar ^a   Jahanzad, Isa ^b,c   Daryani, Nasser Ebrahimi ^b   Ardalan, Farid Azmoodeh ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic hepatitis; Cirrhosis; HCC; IHC; Liver; Liver metastatic tumors; uPA

Indexed keywords

UROKINASE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE;

EID: 34249287030     PISSN: 18119727     EISSN: 18119735     Source Type: Journal    
DOI: 10.3923/ijcr.2007.25.32     Document Type: Article

References (14)

1. Akao, M., Y. Hasebe, N. Okumura, H. Hagiwara, T. Seki and Toyohiko, 2002. Plasminogen activator-plasmin system potentiates the proliferation of hepatocytes in primary culture. Thromb. Res., 107: 169-174.
2. Andreasen, P.A., L. Kjoller, L. Christensen and M.J. Duffy, 1997. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int. J. Cancer, 72: 1-22.
3. Arbabi, B.S., B. Minaee, M. Djamali Zavarhei, S. Fouladdel and E. Azizi, 2006. P-glycopotein and Topoisomerase II alpha expression in advaced gastric cancer patients: Association with clinicopathological findings. IJP, 3: 280-285.
4. Chan, C.F., T.O. Yau, D.Y. Jin, C.M. Wong, S.T. Fan and I.O. Ng, 2004. Evaluation of nuclear factor-kappa B, urokinase-type plasminogen activator and HBx and their clinicopathological significance in hepatocellar carcinoma. Clin. Cancer Res., 10: 4140-4149.
5. Darius, M. and H.E. Blum and E. Hubert, 2005. Pathogenesis of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol., 17: 477-483.
6. De Petro, G., D. Tavian, A. Copeta, N. Portolani, S.M. Giulini and S. Barlati, 1998. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res., 58: 2234-2239.
7. Farazi, P.A. and R.A. DePinho, 2006. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat. Rev. Cancer, 6: 674-687.
8. Funakoshi, H. and T. Nakamura, 2003. Hepatocyte growth factor: From diagnosis to clinical applications. Clin. Chim. Acta, 327: 1-23.
9. Herszenyi, L., M. Plebani, P. Carraro, M. De Paoli, G. Roveroni and R. Cardin et at., 2000. Proteases in gastrointestinal neoplastic diseases. Clin. Chim. Acta, 291: 171-187.
10. Lin, Y., X.F. Me, Y.X. Chen, X. Zhang, X. Zeng and H. Qiang el at., 2005. Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes. Liver Int., 25: 796-803.
11. Nieto-Rodri'Guez, A.A., R. B. He'rnandez-Pando, A.D. Kershenobich and C. L. Rodr Guez-Fragoso, 2001. Expression of urokinase-type plasminogen activator in an experimental model of hepatocarcinoma. Toxicology, 161: 13-23.
12. Rober, F.W. and W.R. Clarke, 2002. Statistical Methods for the Analysis of Biomedical Data. 2nd Edn., Wiley Intersciences, 2002.
13. Rosai, J., 2004. Rosai and Ackerman' s Surgical Pathology, 9th Edn., Mosby.
14. Salgado, S., J. Garcia, J. Vera, F. Siller, M. Bueno and A. Miranda et al., 2000. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol. Ther., 6: 545-551.